Literature DB >> 20080551

Neuregulin 1 regulates pyramidal neuron activity via ErbB4 in parvalbumin-positive interneurons.

Lei Wen1, Yi-Sheng Lu, Xin-Hong Zhu, Xiao-Ming Li, Ran-Sook Woo, Yong-Jun Chen, Dong-Min Yin, Cary Lai, Alvin V Terry, Almira Vazdarjanova, Wen-Cheng Xiong, Lin Mei.   

Abstract

Neuregulin 1 (NRG1) is a trophic factor thought to play a role in neural development. Recent studies suggest that it may regulate neurotransmission, mechanisms of which remain elusive. Here we show that NRG1, via stimulating GABA release from interneurons, inhibits pyramidal neurons in the prefrontal cortex (PFC). Ablation of the NRG1 receptor ErbB4 in parvalbumin (PV)-positive interneurons prevented NRG1 from stimulating GABA release and from inhibiting pyramidal neurons. PV-ErbB4(-/-) mice exhibited schizophrenia-relevant phenotypes similar to those observed in NRG1 or ErbB4 null mutant mice, including hyperactivity, impaired working memory, and deficit in prepulse inhibition (PPI) that was ameliorated by diazepam, a GABA enhancer. These results indicate that NRG1 regulates the activity of pyramidal neurons by promoting GABA release from PV-positive interneurons, identifying a critical function of NRG1 in balancing brain activity. Because both NRG1 and ErbB4 are susceptibility genes of schizophrenia, our study provides insight into potential pathogenic mechanisms of schizophrenia and suggests that PV-ErbB4(-/-) mice may serve as a model in the study of this and relevant brain disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20080551      PMCID: PMC2824309          DOI: 10.1073/pnas.0910302107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  49 in total

Review 1.  Pathophysiologically based treatment interventions in schizophrenia.

Authors:  David A Lewis; Guillermo Gonzalez-Burgos
Journal:  Nat Med       Date:  2006-09       Impact factor: 53.440

Review 2.  Modeling madness in mice: one piece at a time.

Authors:  P Alexander Arguello; Joseph A Gogos
Journal:  Neuron       Date:  2006-10-05       Impact factor: 17.173

Review 3.  Susceptibility genes for schizophrenia: characterisation of mutant mouse models at the level of phenotypic behaviour.

Authors:  Colm M P O'Tuathaigh; Daniela Babovic; Gillian O'Meara; Jeremiah J Clifford; David T Croke; John L Waddington
Journal:  Neurosci Biobehav Rev       Date:  2006-06-19       Impact factor: 8.989

4.  Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle.

Authors:  Hernán García-Rivello; Julián Taranda; Matilde Said; Patricia Cabeza-Meckert; Martin Vila-Petroff; Jorge Scaglione; Sergio Ghio; Ju Chen; Cary Lai; Ruben P Laguens; Kent C Lloyd; Cecilia M Hertig
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-04-29       Impact factor: 4.733

5.  The involvement of ErbB4 with schizophrenia: association and expression studies.

Authors:  Gilad Silberberg; Ariel Darvasi; Ronit Pinkas-Kramarski; Ruth Navon
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2006-03-05       Impact factor: 3.568

6.  Neuregulin-1 reverses long-term potentiation at CA1 hippocampal synapses.

Authors:  Oh-Bin Kwon; Marines Longart; Detlef Vullhorst; Dax A Hoffman; Andres Buonanno
Journal:  J Neurosci       Date:  2005-10-12       Impact factor: 6.167

7.  The neuregulin-1 receptor erbB4 controls glutamatergic synapse maturation and plasticity.

Authors:  Bo Li; Ran-Sook Woo; Lin Mei; Roberto Malinow
Journal:  Neuron       Date:  2007-05-24       Impact factor: 17.173

8.  Neuregulin-1 enhances depolarization-induced GABA release.

Authors:  Ran-Sook Woo; Xiao-Ming Li; Yanmei Tao; Ezekiel Carpenter-Hyland; Yang Z Huang; Janet Weber; Hannah Neiswender; Xian-Ping Dong; Jiong Wu; Martin Gassmann; Cary Lai; Wen-Cheng Xiong; Tian-Ming Gao; Lin Mei
Journal:  Neuron       Date:  2007-05-24       Impact factor: 17.173

9.  Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia.

Authors:  Amanda J Law; Joel E Kleinman; Daniel R Weinberger; Cynthia Shannon Weickert
Journal:  Hum Mol Genet       Date:  2006-12-12       Impact factor: 6.150

10.  Evidence that interaction between neuregulin 1 and its receptor erbB4 increases susceptibility to schizophrenia.

Authors:  Nadine Norton; Valentina Moskvina; Derek W Morris; Nicholas J Bray; Stanley Zammit; Nigel M Williams; Hywel J Williams; Anna C Preece; Sarah Dwyer; Jennifer C Wilkinson; Gillian Spurlock; George Kirov; Paul Buckland; John L Waddington; Michael Gill; Aiden P Corvin; Michael J Owen; Michael C O'Donovan
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2006-01-05       Impact factor: 3.568

View more
  158 in total

1.  Resequencing and association analysis of PTPRA, a possible susceptibility gene for schizophrenia and autism spectrum disorders.

Authors:  Jingrui Xing; Chenyao Wang; Hiroki Kimura; Yuto Takasaki; Shohko Kunimoto; Akira Yoshimi; Yukako Nakamura; Takayoshi Koide; Masahiro Banno; Itaru Kushima; Yota Uno; Takashi Okada; Branko Aleksic; Masashi Ikeda; Nakao Iwata; Norio Ozaki
Journal:  PLoS One       Date:  2014-11-13       Impact factor: 3.240

Review 2.  The contribution of GABAergic dysfunction to neurodevelopmental disorders.

Authors:  Kartik Ramamoorthi; Yingxi Lin
Journal:  Trends Mol Med       Date:  2011-04-21       Impact factor: 11.951

Review 3.  Genetic models of sensorimotor gating: relevance to neuropsychiatric disorders.

Authors:  Susan B Powell; Martin Weber; Mark A Geyer
Journal:  Curr Top Behav Neurosci       Date:  2012

4.  Genetic association of ErbB4 and human cortical GABA levels in vivo.

Authors:  Stefano Marenco; Matthew Geramita; Jan Willem van der Veen; Alan S Barnett; Bhaskar Kolachana; Jun Shen; Daniel R Weinberger; Amanda J Law
Journal:  J Neurosci       Date:  2011-08-10       Impact factor: 6.167

5.  Loss of function studies in mice and genetic association link receptor protein tyrosine phosphatase α to schizophrenia.

Authors:  Nagahide Takahashi; Karin Sandager Nielsen; Branko Aleksic; Steffen Petersen; Masashi Ikeda; Itaru Kushima; Nathalie Vacaresse; Hiroshi Ujike; Nakao Iwata; Véronique Dubreuil; Naheed Mirza; Takeshi Sakurai; Norio Ozaki; Joseph D Buxbaum; Jan Sap
Journal:  Biol Psychiatry       Date:  2011-08-10       Impact factor: 13.382

Review 6.  Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap.

Authors:  Judith Pratt; Catherine Winchester; Neil Dawson; Brian Morris
Journal:  Nat Rev Drug Discov       Date:  2012-06-22       Impact factor: 84.694

Review 7.  Concise review: the promise of human induced pluripotent stem cell-based studies of schizophrenia.

Authors:  Kristen J Brennand; Fred H Gage
Journal:  Stem Cells       Date:  2011-12       Impact factor: 6.277

Review 8.  Neuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway.

Authors:  Chao Deng; Bo Pan; Martin Engel; Xu-Feng Huang
Journal:  Psychopharmacology (Berl)       Date:  2013-02-07       Impact factor: 4.530

9.  Disruption of hippocampal neuregulin 1-ErbB4 signaling contributes to the hippocampus-dependent cognitive impairment induced by isoflurane in aged mice.

Authors:  Xiao-Min Li; Fan Su; Mu-Huo Ji; Guang-Fen Zhang; Li-Li Qiu; Min Jia; Jun Gao; Zhongcong Xie; Jian-Jun Yang
Journal:  Anesthesiology       Date:  2014-07       Impact factor: 7.892

10.  Neuregulin-1 impairs the long-term depression of hippocampal inhibitory synapses by facilitating the degradation of endocannabinoid 2-AG.

Authors:  Huizhi Du; In-Kiu Kwon; Jimok Kim
Journal:  J Neurosci       Date:  2013-09-18       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.